Compare Etsy Inc (ETSY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Incyte Corporation — how do they compare? Etsy Inc trades at $76.71 (market cap $6.90B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 3.3× Etsy Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Incyte Corporation for 33 Days on average.
| ETSY | INCY | |
|---|---|---|
Market Cap | $6.90B | $22.85B |
Volume | 2,923,867 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $129.93 |
52-Week Low | $44.05 | $83.80 |
Typical Hold Time | 67 Days | 33 Days |
Enterprise Value | $8.85B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $76.71, up 7.3% in the last 24 hours, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and a consensus analyst price target of $85.94. Revenue grew to $2.88B in 2025, though net income margin declined to 5.65%. Recent news highlights AI integration and payment partnerships as growth catalysts.
Outlook is positive with analyst support and strategic initiatives, but risks include high debt, margin pressure, and competitive threats. The stock offers upside to the price target but requires monitoring of execution and macroeconomic factors.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
